FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 15, 2018

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Primary Focal Segmental Glomerulosclerosis
Interventions
DRUG

CXA-10

CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)

Trial Locations (24)

10461

Albert Einstein College of Medicine, Montefiore, The Bronx

18017

Northeast Clinical Research Center (NCRC), Bethlehem

19104

University of Pennsylvania, Philadelphia

19803

A.I. duPont Hospital for Children, Wilmington

23298

Virginia Commonwealth University, Richmond

28204

Metrolina Nephrology Associates, Charlotte

28207

Levine Children's Hospital, Charlotte

33136

University of Miami, Miami

35805

Alabama Neurology Consultants, Huntsville

37205

Nephrology Associates, Franklin

44195

Cleveland Clinic, Cleveland

48066

St. Clair Nephrology Research, Roseville

48109

University of Michigan, Ann Arbor

60521

Nephrology Associates of Northern Illinois and Indiana (NANI), Chicago

64111

Clinical Research Consultants-KCMO, Kansas City

71101

Northwest Louisiana Nephrology, Shreveport

75115

Renal Disease Research Institute, DeSoto

79106

Texas Tech, Amarillo

79935

El Paso Medical Research, El Paso

94304

Stanford University, Palo Alto

98104

The Polyclinic, Seattle

99204

Providence Sacred Heart Medical Center and Children's Hospital, Spokane

90048-9978

Cedars Sinai Medical Center, Los Angeles

01107

Kidney Care and Transplant Services of New England, Springfield

All Listed Sponsors
collaborator

Kidney Research Network, formerly NephCure Accelerating Cures Institute

UNKNOWN

collaborator

Medpace, Inc.

INDUSTRY

collaborator

MicroConstants

UNKNOWN

collaborator

Arkana Labs

UNKNOWN

collaborator

NephCure Kidney International

UNKNOWN

lead

Complexa, Inc.

INDUSTRY